Bruker (BRKR) AI Stock Analysis

• Market Cap: $6.20B
• Dividend Yield: 0.49%
• Average Volume (3M): 1.98M
• Price to Earnings (P/E): 77.9
• Beta (1Y): 1.14
• Revenue Growth: 14.84%
• EPS Growth: -80.87%
• Country: US
• Employees: 11,396
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Devices
• EPS (TTM): 0.47
• Shares Outstanding: 151,531,800
• 10 Day Avg. Volume: 2,208,187
• 30 Day Avg. Volume: 1,976,332
• PEG Ratio: 3.69
• Price to Book (P/B): 9.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 71.03
• Enterprise Value/Market Cap: 1.73
• Enterprise Value/Revenue: 0.81
• Enterprise Value/Gross Profit: 6.37
• Enterprise Value/Ebitda: 5.24
• 1Y Price Target: $51.56
• Price Target Upside: 22.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 73 Outperform
• Price Target: $44.00 ▲(4.31%Upside)

Bruker's strong financial performance and strategic corporate actions are key strengths, particularly in revenue growth and cash management. However, high leverage, valuation concerns, and potential revenue impacts from policy changes pose risks. Positive corporate events and a solid earnings call outlook partially offset these challenges, resulting in a moderate overall stock score.

Positive Factors

Market Expansion

ASMS launches are meaningful and expand the total addressable market threefold, with a focus on timsOMNI and timsMetabo, indicating a new market opportunity with little competition.

Revenue Growth

The security and defense business is gaining momentum, with increasing demand for trace detection at airports and by airlines, potentially boosting revenue.

Negative Factors

Operational Challenges

Given softness in FY24-25, Bruker’s medium-term targets are unlikely to be realized under the originally planned cadence.

Regulatory and Policy Challenges

Headwinds in the U.S. are expected to persist into 2026 with a potential budget reduction, creating a challenging environment for BRKR.

Tariffs and Trade Policy

Guidance now assumes $100 million gross top-line headwinds from tariffs and policy changes, partially offset by pricing and mitigation actions of $20 million for a net $80 million top-line headwind.

Bruker Business Overview & Revenue Model

Company Description

Bruker Corporation (BRKR) is a global leader in scientific instruments and solutions for molecular and materials research, as well as industrial and applied analysis. The company operates through two main segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). Bruker offers a diverse range of high-performance scientific instruments and analytical solutions, including NMR, mass spectrometry, X-ray diffraction, and imaging systems, among others. These tools are essential for advancing research in life sciences, pharmaceuticals, biotechnology, and materials science.

How the Company Makes Money

Bruker makes money primarily through the sale of its advanced scientific instruments and related services. The company generates revenue from the sale of its high-performance analytical and diagnostic solutions across its key segments. In the Bruker Scientific Instruments (BSI) segment, revenue is driven by the sale of products and services related to life science research, applied markets, industrial and clinical applications. The Bruker Energy & Supercon Technologies (BEST) segment contributes to revenue through the supply of superconducting materials and devices. Additionally, Bruker benefits from ongoing service contracts, maintenance, and support agreements that provide a recurring revenue stream. Strategic partnerships and collaborations with academic, governmental, and industrial institutions also enhance revenue opportunities by driving innovation and expanding the application of Bruker's technologies.

Bruker Financial Statement Overview

Summary

Bruker's financials reflect strong revenue growth and efficient cash flow management amidst rising costs and increased leverage. While profitability margins have faced some pressure, the company's ability to generate cash supports its financial health. Balance sheet leverage is a potential risk that needs monitoring, but the equity foundation remains stable, suggesting resilience in the face of industry challenges.

Income Statement

The company exhibits strong revenue growth with a 14.52% increase from 2023 to 2024 and consistent gross profit margins around 48-50%. However, net profit margins have declined recently from 3.36% TTM (Trailing-Twelve-Months) compared to 3.36% in 2024, indicating increased expenses or cost pressures. EBIT and EBITDA margins are stable yet slightly compressed due to rising operating costs.

Balance Sheet

The balance sheet shows a solid equity ratio of approximately 30.62% TTM, reflecting a stable financial base. The debt-to-equity ratio is high at 1.16 TTM, suggesting significant leverage. Although the company has increased its assets, the rise in debt levels could pose risks if not managed carefully.

Cash Flow

Cash flow analysis indicates robust operating cash flows relative to net income, with a ratio of 3.70 TTM. Free cash flow showed a strong growth rate of 28.35% TTM, highlighting effective cash management. Despite substantial investment activities, the company maintains positive free cash flow, supporting its operational and strategic initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.45B	3.37B	2.96B	2.53B	2.42B	1.99B
Gross Profit	1.68B	1.65B	1.51B	1.31B	1.21B	939.80M
EBITDA	458.20M	438.60M	599.00M	545.30M	497.10M	320.70M
Net Income	79.60M	113.10M	427.20M	296.60M	277.10M	157.80M
Balance Sheet
Total Assets	5.93B	5.81B	4.25B	3.62B	3.65B	3.05B
Cash, Cash Equivalents and Short-Term Investments	184.20M	183.40M	488.30M	645.50M	1.17B	731.80M
Total Debt	2.11B	2.25B	1.38B	1.22B	1.33B	891.50M
Total Liabilities	4.08B	3.99B	2.84B	2.49B	2.57B	2.07B
Stockholders Equity	1.82B	1.78B	1.38B	1.13B	1.08B	975.60M
Cash Flow
Free Cash Flow	174.60M	136.00M	243.20M	143.00M	190.40M	235.00M
Operating Cash Flow	294.50M	251.30M	350.10M	262.00M	282.40M	333.20M
Investing Cash Flow	-1.48B	-1.76B	-326.00M	-239.30M	-192.40M	-193.70M
Financing Cash Flow	1.03B	1.23B	-193.40M	-415.20M	318.70M	-161.60M

Bruker Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 42.18
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 42.18 is above the 20-day moving average (MA) of 38.69, above the 50-day MA of 38.41, and below the 200-day MA of 51.29, indicating a neutral trend. The MACD of 0.56 indicates Negative momentum. The RSI at 64.07 is Neutral, neither overbought nor oversold. The STOCH value of 73.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.

Bruker Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BRKR	73 Outperform	$6.20B	77.95	4.92%	0.49%	14.84%	-80.87%
ITGR	67 Neutral	$4.21B	57.82	4.98%	―	7.41%	-22.10%
LIVN	66 Neutral	$2.50B	30.62	-19.69%	―	7.97%	-592.40%
IRTC	64 Neutral	$4.87B	―	-111.13%	―	20.54%	25.73%
XTNT	54 Neutral	$85.80M	―	-26.20%	―	20.81%	-498.66%
BIO	53 Neutral	$6.55B	―	-27.51%	―	-2.46%	-637.11%
Sector *	50 Neutral	kr5.18B	11.75	-82.66%	10.10%	36.04%	27.80%

Bruker Corporate Events

Bruker Approves 2026 Incentive Compensation Plan

Bruker Corporation’s stockholders approved the 2026 Incentive Compensation Plan during the 2025 Annual Meeting held on May 29, 2025. The plan, effective February 19, 2026, will replace the 2016 Incentive Compensation Plan and authorizes up to 12,000,000 shares for issuance. It will be administered by the Compensation Committee and offers various awards to non-employee directors, employees, and key advisors. The plan will terminate on May 28, 2035, unless ended earlier. Additionally, the meeting included the election of directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent auditor for 2025.

The most recent analyst rating on (BRKR) stock is a Hold with a $74.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.

Bruker Announces Settlement with 10x Genomics

On May 14, 2025, Bruker Corporation announced a global settlement with 10x Genomics to resolve patent disputes, resulting in the dismissal of multiple litigations and the establishment of cross-license agreements. This settlement allows Bruker to focus on its spatial biology platforms, CosMx® and GeoMx®, enhancing research in oncology and neurobiology without legal distractions, thereby benefiting the scientific community and advancing precision medicine.

The most recent analyst rating on (BRKR) stock is a Hold with a $74.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.